Lamivudine and Zidovudine
- Product NDC
- 71335-0141
- 11-digit product format
- 713350141
- Labeler code
- 71335
- Product ID
- 71335-0141_703af9cd-c96c-4129-bd7f-a5e4973b07a0
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Lamivudine and Zidovudine
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- Bryant Ranch Prepack
- Application
- ANDA079128
- Marketing category
- ANDA
- Marketing start
- 2016-12-10
- Marketing end
- 0000-00-00
- Substance
- LAMIVUDINE; ZIDOVUDINE
- Active strength
- 150 mg/1; mg/1
- Pharmacologic classes
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2021-12-31
- Current FDA listing
- Historical FDA.report record
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 71335-0141 | LAMIVUDINE AND ZIDOVUDINE TABLET [BRYANT RANCH PREPACK] | 4 | Legacy NDC | 20241004_1add9fef-69e4-4f74-a17c-99d59de28441.zip |
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 71335-0141-1 | 71335014101 | 6 TABLET in 1 BOTTLE (71335-0141-1) | 6 tablet | 2016-12-10 | 0000-00-00 | No | No | Current |
| 71335-0141-2 | 71335014102 | 60 TABLET in 1 BOTTLE (71335-0141-2) | 60 tablet | 2016-12-10 | 0000-00-00 | No | No | Current |
| 71335-0141-3 | 71335014103 | 4 TABLET in 1 BOTTLE (71335-0141-3) | 4 tablet | 2016-12-10 | 0000-00-00 | No | No | Current |